Form 4: Vor Biopharma Insider Sells $3M in Stock

Reprogrammed Interchange LLC, a 10% owner and entity associated with director Reid Hoffman, sold 96,657 shares of Vor Biopharma common stock for approximately $3 million.

Summary

• Reprogrammed Interchange LLC, a 10% owner and entity linked to director Reid Hoffman, reported multiple sales of Vor Biopharma Inc. common stock.
• A total of 96,657 shares were sold across four transactions between October 10, 2025, and October 14, 2025.
• The sales were executed at weighted average prices ranging from $30.3192 to $33.0873 per share.
• The total proceeds from these sales amount to approximately $3,004,640.
• Following these transactions, Reprogrammed Interchange LLC beneficially owns 1,278,118 shares of Vor Biopharma common stock.
• The transactions were conducted under a Rule 10b5-1 trading plan.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by a 10% owner and director-affiliated entity. While the sales were under a 10b5-1 plan, which mitigates the immediate negative signal, the sheer volume of shares sold still indicates a reduction in insider exposure to the company's stock.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not necessarily based on new, non-public information.

Negatives

• A significant insider (10% owner and director-affiliated entity) sold a substantial number of shares, which can be perceived negatively by the market.
• The sales represent a reduction in the insider's direct beneficial ownership in the company.

Risks

• Investor perception risk: Significant insider selling, even if pre-planned, can sometimes be interpreted by the market as a lack of confidence, potentially leading to downward pressure on the stock price.

Future Outlook

NA

Management Comments

• Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.
• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Industry Context

This Form 4 filing reports routine insider trading activity and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• The transactions involve Reprogrammed Interchange LLC, a 10% owner, and Reid Hoffman, a director, indicating a related party transaction in the context of insider trading.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to decreased confidence and downward pressure on the stock price.
• Management/Employees: No direct impact mentioned, but a significant insider sale could affect morale or perception of company stability.

Key Dates

Recommendation

While the insider selling by a 10% owner and director-affiliated entity is a negative signal, the fact that it was executed under a Rule 10b5-1 plan suggests it was pre-scheduled and not necessarily based on new, adverse non-public information. This mitigates the immediate 'sell' signal. However, the substantial volume of shares sold warrants caution, preventing a 'buy' recommendation. A 'hold' recommendation is appropriate to observe market reaction and any further developments, as the selling reduces insider alignment with common shareholders.

Keywords

Vor Biopharma, VOR, SEC Form 4, Insider Selling, Reprogrammed Interchange LLC, Reid Hoffman, Stock Sale, 10b5-1 Plan, Beneficial Ownership